Document is current
Any future updates will be listed below
-
Authors
Zhao, Jing https://orcid.org/0000-0002-4520-6307
Ikezu, Tadafumi C.
Lu, Wenyan
Macyczko, Jesse R.
Li, Yonghe
Lewis-Tuffin, Laura J.
Martens, Yuka A.
Ren, Yingxue
Zhu, Yiyang
Asmann, Yan W.
Ertekin-Taner, Nilüfer
Kanekiyo, Takahisa
Bu, Guojun
-
Funding
Funding for this research was provided by:
NIH Blueprint for Neuroscience Research (U19AG069701, RF1AG057181)
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 9 August 2023
First Online: 21 August 2023
Declarations
:
: Human iPSC lines were obtained from Mayo Clinic patients under approved IRB protocols with patient consent for research. The reference IRB number is 12-002562 with the title “Human skin fibroblast and lymphocyte-derived induced pluripotent stem cells (iPS) and their use in studying Alzheimer’s disease (AD) and other neurodegenerative disorders.”. It was first approved by Mayo Clinic Institutional Review Board on 05/01/2012.
: Not applicable.
: G.B. and Y.M. is currently an employee of SciNeuro Pharmaceuticals. G.B. had previously consulted for AbbVie, E-Scape, Eisai, Vida Ventures, and Kisbee Therapeutics. All other authors declare no competing interests.
